ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!

Lung Cancer Canada (LCC) is seeking ROS1 positive non-small cell lung cancer (NSCLC) patients and caregivers who have past or present treatment experience with ENTRECTINIB to share their experiences. This information will be used to provide patient/caregiver input that will help in determining accessibility of this drug for lung cancer patients in Canada. LCC and lung cancer patients appreciate your help with this.

Information can be provided in two ways:

1. Contact Iwo Effiong by email ( to schedule a short interview.

2. Provide answers to a few survey questions at

Thanks for helping ROS1+ NSCLC patients obtain access to effective targeted therapies worldwide.

Published by

Gray Connections

I was diagnosed with non-small cell lung cancer in May 2011. The cancer became metastatic in October 2011. No, I never smoked anything (except a salmon). I've had no evidence of disease since January 2013 thanks to precision medicine, clinical trials, and other patients. ANYONE can get lung cancer. Using my engineering degrees (MIT SBME 1978, Caltech Aeronautics MS 1984 and ENGR 1986), I enjoyed a 20-year career in aerospace systems engineering as a technical translator of sorts: I researched a scientific or engineering subject and helped others understand how this new gizmo could benefit them. In the time I have left, I want to use my skills to help others who have lung cancer, and increase the visibility and knowledge of lung cancer among those who don't. I also study brain research, enjoy traveling, write science fiction, and geek out about all sorts of science stuff.

2 thoughts on “ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!

  1. Will send to our patients too.

    Bonnie J. Addario
    Co-Founder and Chair


Comments are closed.